Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Subscribe To Our Newsletter & Stay Updated